Search research articles
Contact Us
Filters
Showing results (451-460 of 940) with videos related to
Page
of 94
Sort By:
Neuro-Oncology
|
October 11, 2017
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
Bogdana Suchorska, Armin Giese, Annamaria Biczok, et al.
Neuromuscular Disorders : NMD
|
May 1, 2025
Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report
Lukasz Kolakowski, Olivia Zschau, Jérôme Bonzon, et al.
Annals of Neurology
|
July 23, 2013
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment
Sven Schippling, Christian Kempf, Fabian Büchele, et al.
Neurosurgical Review
|
December 26, 2025
Intrinsic and extrinsic risk factors in tumor-related epilepsy
Omar Rafi, Alessandro Carretta, Luca Zanuttini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2017
Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer
Emilie Le Rhun, Nicolas Bertrand, Aurélie Dumont, et al.
Cerebellum (London, England)
|
August 2, 2020
Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome
Martina Sebök, Christiaan Hendrik Bas van Niftrik, Matthias Halter, et al.
Brain : a Journal of Neurology
|
February 5, 2013
Integrin control of the transforming growth factor-β pathway in glioblastoma
Patrick Roth, Manuela Silginer, Simon L Goodman, et al.
Neuro-Oncology
|
August 2, 2019
Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
Julia Furtner, Els Genbrugge, Thierry Gorlia, et al.
Nature Reviews. Neurology
|
June 11, 2014
MGMT testing--the challenges for biomarker-based glioma treatment
Wolfgang Wick, Michael Weller, Martin van den Bent, et al.
Journal of Neurochemistry
|
October 28, 2016
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models
Hannah Schneider, Emese Szabo, Raquel A C Machado, et al.
Page
of 94
Search research articles
Search
Showing results (451-460 of 940) with videos related to
Sort By:
Page
of 94
Neuro-Oncology
|
October 11, 2017
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
Bogdana Suchorska, Armin Giese, Annamaria Biczok, et al.
Neuromuscular Disorders : NMD
|
May 1, 2025
Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report
Lukasz Kolakowski, Olivia Zschau, Jérôme Bonzon, et al.
Annals of Neurology
|
July 23, 2013
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment
Sven Schippling, Christian Kempf, Fabian Büchele, et al.
Neurosurgical Review
|
December 26, 2025
Intrinsic and extrinsic risk factors in tumor-related epilepsy
Omar Rafi, Alessandro Carretta, Luca Zanuttini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2017
Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer
Emilie Le Rhun, Nicolas Bertrand, Aurélie Dumont, et al.
Cerebellum (London, England)
|
August 2, 2020
Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome
Martina Sebök, Christiaan Hendrik Bas van Niftrik, Matthias Halter, et al.
Brain : a Journal of Neurology
|
February 5, 2013
Integrin control of the transforming growth factor-β pathway in glioblastoma
Patrick Roth, Manuela Silginer, Simon L Goodman, et al.
Neuro-Oncology
|
August 2, 2019
Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
Julia Furtner, Els Genbrugge, Thierry Gorlia, et al.
Nature Reviews. Neurology
|
June 11, 2014
MGMT testing--the challenges for biomarker-based glioma treatment
Wolfgang Wick, Michael Weller, Martin van den Bent, et al.
Journal of Neurochemistry
|
October 28, 2016
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models
Hannah Schneider, Emese Szabo, Raquel A C Machado, et al.
Page
of 94